NeuroStar Unveils Two Significant Publications on TMS Therapy for DepressionAdvancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools
Health Care Service Corporation Adds First-Line TMS Coverage for AdolescentsPolicy update increases access for millions covered by HCSC BlueCross BlueShield policies
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and AdultsBlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression
NeuroStar® Releases Software Upgrades to Elevate Patient CareUpgrades improve communication, streamline data management, and strengthen security
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enstar Group Limited (Nasdaq – ESGR), PetIQ, Inc. (Nasdaq – PETQ), Greenbrook TMS, Inc. (OTC – GBNHF), GSE Solutions, Inc. (Nasdaq – GVP)BALA CYNWYD, Pa., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful StoriesNeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar UniversityCelebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health MonthNew initiative aims to provide information and resources for teen mental health amidst rising public health concerns
California Medicaid Adds TMS Access for 14.8 Million Adolescents and AdultsNeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal
NeuroStar® Launches Better Me Provider Program NationwideThe first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual MeetingEarly prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024
Humana Is First Commercial Payer to Address TMS Therapy Coverage for AdolescentsPolicy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthThe Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care NetworkMALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (
NASDAQSTIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement AccessoryNew accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providers
NeuroStar TMS Receives Expanded Regulatory Approval in JapanTechnological advances reduce time and increase efficiency for MDD treatment
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy CoveragePolicy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives
